Publications by authors named "J Mrus"
Article Synopsis
- - The ATLAS and FLAIR studies tested a long-acting injectable treatment (cabotegravir + rilpivirine) for HIV-1 against current daily oral regimens in adults with suppressed viral loads.
- - After 48 weeks, the injectable treatment showed similar effectiveness in keeping HIV-1 levels low compared to the daily regimen, with noninferiority criteria met and only a small percentage experiencing treatment failure.
- - While injection site reactions were common, overall safety profiles were comparable, indicating that monthly injections could be a viable option for managing HIV-1.
Background: Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, literature on physician drivers for prescribing DTG 2DR is sparse. This study evaluated treatment patterns of DTG 2DR components in clinical practice in the US.
Methods: This was a retrospective chart review in adult patients in care in the US with HIV-1 who received DTG 2DR prior to July 31, 2017, with follow-up until January 30, 2018.
Background: Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence.
Methods: In this phase 3, open-label, multicenter, noninferiority trial involving patients who had had plasma HIV-1 RNA levels of less than 50 copies per milliliter for at least 6 months while taking standard oral antiretroviral therapy, we randomly assigned participants (1:1) to either continue their oral therapy or switch to monthly intramuscular injections of long-acting cabotegravir, an HIV-1 integrase strand-transfer inhibitor, and long-acting rilpivirine, a nonnucleoside reverse-transcriptase inhibitor. The primary end point was the percentage of participants with an HIV-1 RNA level of 50 copies per milliliter or higher at week 48, determined with the use of the Food and Drug Administration snapshot algorithm.
Article Synopsis
- The study compares the clinical effectiveness of four antiretroviral therapy (ART) agents—Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL), and Darunavir (DRV)—in preventing virologic failure among HIV-positive individuals.
- The analysis included 4049 ART-naïve patients and found that those starting on DTG had significantly higher rates of viral suppression compared to those on RAL and DRV, with rates of 78.7% for DTG versus only 51.9% and 48.6% for RAL and DRV, respectively.
- This indicates that DTG is more effective in achieving viral suppression and has lower associated
Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality currently under development as an alternative to daily oral ART. The LATTE-2 study (ClinicalTrials.gov identifier NCT02120352) showed that cabotegravir LA + rilpivirine LA maintained virologic suppression through 96 weeks and included further exploration of patient-reported treatment outcomes with an LA injectable form of treatment.
View Article and Find Full Text PDF